As expected, tumor burdens were all extenuated in the combination treatment groups, as reflected by significantly suppressed M protein levels (Figure 7G), as well as remarkably fewer CD138+ cells remaining in the murine bone marrow (Supplemental Figure 9E). The gene discussed is MYOM2; the disease is neoplasm.